IVIG immunotherapy protects against synaptic dysfunction in Alzheimer's disease through complement anaphylatoxin C5a-mediated AMPA-CREB-C/EBP signaling pathway

Bing Gong, Yong Pan, Wei Zhao, Lindsay Knable, Prashant Vempati, Shimul Begum, Lap Ho, Jun Wang, Shrishailam Yemul, Scott Barnum, Amanda Bilski, Ben Y. Gong, Giulio M. Pasinetti

Research output: Contribution to journalArticlepeer-review

32 Scopus citations

Abstract

Background: Complement component C5-derived C5a locally generated in the brain has been shown to protect against glutamate-induced neuronal apoptosis and beta-amyloid (Aβ) toxicity, but the mechanism is not clear. In this study, we tested the hypothesis that C5a influences upstream signal transduction pathways associated with cAMP-response element-binding protein (CREB) activation, in which alterations of CREB levels are associated with cognitive deterioration in AD. Methods: CREB signaling pathway, synaptic plasticity and cognitive function were studied in C5a receptor knockout mice (C5aR-/-), C5a over expressing mice (C5a/GFAP) and in Tg2576 mice, an AD mouse model. Results: (1) Cognitive function is severely impaired in C5aR-/- mice, coincident with the down-regulated CREB/CEBP pathway in brain. (2) Either the application of recombinant-human-C5a (hrC5a) or exogenous expression of C5a in the brain of a mouse model (C5a/GFAP) enhances this pathway. (3) Application of hrC5a in brain slices from Tg2576 mice significantly improves deficits in long-term potentiation (LTP), while this effect is blocked by a specific AMPA receptor antagonist. (4) Searching for a pharmacological approach to locally mediate C5a responses in the brain, we found that low-dose human intravenous immunoglobulin (IVIG) treatment improves synaptic plasticity and cognitive function through C5a-mediated induction of the CREB/CEBP pathway, while the levels of Aβ in the brain are not significantly affected. Conclusion: This study for the first time provides novel evidence suggesting that C5a may beneficially influence cognitive function in AD through an up-regulation of AMPA-CREB signaling pathway. IVIG may systematically improve cognitive function in AD brain by passing Aβ toxicity.

Original languageEnglish
Pages (from-to)619-629
Number of pages11
JournalMolecular Immunology
Volume56
Issue number4
DOIs
StatePublished - 31 Dec 2013

Keywords

  • Alzheimer's disease
  • Cognitive function
  • Complement component C5a
  • IVIG
  • LTP
  • PCREB

Fingerprint

Dive into the research topics of 'IVIG immunotherapy protects against synaptic dysfunction in Alzheimer's disease through complement anaphylatoxin C5a-mediated AMPA-CREB-C/EBP signaling pathway'. Together they form a unique fingerprint.

Cite this